Biochemical Modulation of 5-Fluorouracil with Pyrimidines, Purines and their Nucleosides

  • Giovanni Santelli
Part of the Developments in Oncology book series (DION, volume 47)

Abstract

Attempts at improving the selectivity of FUra by biochemical modulation with purine and pyrimidines were carried out soon after the synthesis and early clinical trials of FUra (1). The coupling of an antimetabolite with physiological metabolites received much attention in those years after the successful use of the pair methotrexate-folinic acid (2, 3). The hope was to discover a similar combination containing FUra that would allow its administration beyond the maximal tolerated dose and possibly achieve a better selectivity for tumor cells. After it became clear that the metabolic pathways involved in the activation of FUra to cytotoxic nucleotides were complex, and regulated by enzymes in the presence of feed-back mechanisms, a whole new area was opened to investigation. After the initial disappointing results, this approach was almost abandoned, however, recently some important new data concerning the mechanism of action of FUra have revitalized the field. I will outline in this review the most important contributions to this area, focusing on the use of pyrimidines, purines and their nucleosides, as well as the need for future studies.

Keywords

Toxicity Leukemia Monophosphate Diphosphate Guanosine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Burchenal JH, Oettgen HF, Reppert JA, Coley V: Studies on the synergism of fluorinated pyrimidines and certain pyrimidines and purine derivatives against transplanted mouse leukemia. Cancer Chemotherap. Rep. 6: 1–5, 1960.Google Scholar
  2. 2.
    Goldin A, Mantel N: The employment of combinations of drugs in the chemotherapy of neoplasia: A review. Cancer Res. 17: 635–654, 1957.PubMedGoogle Scholar
  3. 3.
    Goldin A, Venditti JM, Kline I, Mantel N: Eradication of leukaemic cells (L1210) by methotrexate and methotrexate plus citrovorum factor. Nature 212: 1548–1550, 1966.PubMedCrossRefGoogle Scholar
  4. 4.
    Duschinski R, Pleven E, Heidelberger C: The synthesis of 5-fluoropyrimidines. J. Am. Chem. Soc. 79: 4559–4560, 1957.CrossRefGoogle Scholar
  5. 5.
    Danneberg P, Montag BJ, Heidelberger C: Studies on fluorinated pyrimidines. IV. Effects on nucleic acid metabolism in vivo. Cancer Res. 18: 329–334, 1958.Google Scholar
  6. 6.
    Mandel G: The incorporation of 5-fluorouracil into RNA and its molecular consequences. Prog. Molec. Subcell. Biol. 1: 82–135, 1969.Google Scholar
  7. 7.
    Kufe DW, Major PP: 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J. Biol. Chem. 256: 9802–9805, 1981.PubMedGoogle Scholar
  8. 8.
    Major PP, Egan E, Herrick D, Kufe DW: 5-Fluorouracil incorporation in DNA of human breast carcinoma cells. Cancer Res. 42: 3005–3009, 1982.PubMedGoogle Scholar
  9. 9.
    Maybaum J, Ullman B, Mandel HG et al: Regulation of RNA-and DNA-directed action of 5-fluoropyrimidines in mouse T-lymphoma (S-49). Cancer Res. 40: 4209–4215, 1980.PubMedGoogle Scholar
  10. 10.
    Peters GJ, Laurensee E, Lankelma J et al: Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucle-otide sugars. Eur. J. Cancer Clin. Oncol. 20: 1425–1431, 1984.Google Scholar
  11. 11.
    Sommadossi J-P, Gewirtz DA, Cross DS et al: Modulation of 5-fluorouracil catabolism in isolated hepatocytes with enhancement of 5-fluorouracil glucuronide formation. Cancer Res. 45: 116–121, 1985.PubMedGoogle Scholar
  12. 12.
    Chaudhuri NK, Mukherjee KL, Heidelberger C: Studies on fluorinated pyrimidines. VII. The degradative pathway. Biochem. Pharmacol. 1: 328–341, 1958.Google Scholar
  13. 13.
    Ikenaka K, Shirasaka T, Kitano S, Fujii S: Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann. 70: 353–359, 1979.PubMedGoogle Scholar
  14. 14.
    Schwartz PM, Turek PJ, Hyde CM et al: Altered plasma kinetics of 5-FU at high dosage in rat and man. Cancer Treat. Rep. 69: 133–136, 1985.PubMedGoogle Scholar
  15. 15.
    Cooper GM, Dunning WF, Greer S: Role of catabolism in pyrimidine utilization for nucleic acid synthesis in vivo. Cancer Res. 32: 390–397, 1972.PubMedGoogle Scholar
  16. 16.
    Fujii S, Ikenaka K, Fukushima M, Shirasaka T: Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann. 69: 763–772, 1978.PubMedGoogle Scholar
  17. 17.
    Sommadossi J-P, Gewirts DA, Cross DS et al: Modulation of 5-fluorouracil catabolism in isolated rat hepatocytes with enhancement of 5-fluorouracil glucuronide formation. Cancer Res. 45: 116–121, 1985.PubMedGoogle Scholar
  18. 18.
    Heidelberger C, Chaudhuri NK, Danneberg P et al: Fluorinated pyrimidines, a new class of tumour-inhibiting compounds. Nature 179: 663–666, 1957.PubMedCrossRefGoogle Scholar
  19. 19.
    Burchenal JH, Holmberg EAD, Fox JJ et al: The effects of 5-fluorodeoxycytidine, 5-fluorodeoxyuridine and related compounds on transplanted mouse leukemias. Cancer Res. 19: 494–500, 1959.PubMedGoogle Scholar
  20. 20.
    Burchenal JH, Oettgen HF, Reppert JA, Coley V: Studies on the synergism of fluorinated pyrimidines and certain pyrimidines and purine derivatives against transplanted mouse leukemia. Cancer Chemother. Rep. 6: 1–5, 1960.PubMedGoogle Scholar
  21. 21.
    Rich MA, Saslaw L, Eidinoff ML: Some differences among various mammalian cell lines in reversal of growth inhibition by 5-fluorouracil. Proc. Soc. Exp. Biol. Med. 103: 791–796, 1960.Google Scholar
  22. 22.
    Umeda M, Heidelberger C: Comparative studies of fluorinated pyrimidines with various cell lines. Cancer Res. 28: 2529–2538, 1968.PubMedGoogle Scholar
  23. 23.
    Roobol C, De Dobbeleer GBE, Bernheim JL: 5-Fluorouracil and 5-fluoro-2′-deoxyuridine follow different metabolic pathways in the induction of cell lethality in L1210 leukaemia. Br. J. Cancer 49: 739–744, 1984.PubMedCrossRefGoogle Scholar
  24. 24.
    Madoc-Jones H, Bruce WR: On the mechanism of the lethal action of 5-fluorouracil on mouse L cells. Cancer Res. 28: 1976–1981, 1968.PubMedGoogle Scholar
  25. 25.
    Kanzawa F, Hoshi A, Kuretani K: Differences between 5-fluoro-2′-deoxyuridine and 5-fluorouridine in their cyto-toxic effect on growth of murine lymphoma L5178Y cells in vivo and in vitro systems. Eur. J. Cancer 16: 1087–1092, 1980.PubMedGoogle Scholar
  26. 26.
    Santelli G, Valeriote F: In vivo enhancement of 5-fluorouracil cytotoxicity to AKR leukemia cells by thymidine in mice. J. Natl. Cancer Inst. 61: 843–847, 1978.PubMedGoogle Scholar
  27. 27.
    Martin DS, Nayak R, Sawyer RC et al: Enhancement of 5-fluorouracil chemotherapy with emphasis on the use of excess thymidine. The Cancer Bull. 30: 219–224, 1978.Google Scholar
  28. 28.
    Woodcock TM, Martin DS, Damin LAM et al: Combination clinical trials with thymidine and fluouracil: A Phase I and clinical pharmacologie evaluation. Cancer 45: 1135–1143, 1980.PubMedCrossRefGoogle Scholar
  29. 29.
    Jato J, Windheuser JJ: 5-Fluorouracil and derivatives in cancer chemotherapy. III. In vivo enhancement of anti-tumor activity of 5-fluorouracil (FU) and 5-fluoro-2′-deoxyuridine (FUDR). J. Pharm. Sci. 62: 1975–1978, 1973.Google Scholar
  30. 30.
    Santelli G, Valeriote F: Schedule-dependent cytotoxicity of 5-fluorouracil in mice. J. Natl. Cancer Inst., in press.Google Scholar
  31. 31.
    Spiegelman S, Sawyer R, Nayak et al: Improving the antitumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation. Proc. Natl. Acad. Sci. USA 77: 4966–4970, 1980.PubMedCrossRefGoogle Scholar
  32. 32.
    Moore EC, Hurlbert RB: Regulation of mammalian deoxyribonucleotide biosynthesis by nucleotides as activators and inhibitors. J. Biol. Chem. 241: 4802–4809, 1966.PubMedGoogle Scholar
  33. 33.
    Lowe JK, Grindey GB: Inhibition of growth rate and deoxynucleoside triphosphate concentrations in cultured leukemia L1210 cells. Mol. Pharmacol. 12: 177–184, 1976.PubMedGoogle Scholar
  34. 34.
    Moran RG, Danenberg PV, Heidelberger C: Theapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis. Biochem. Pharmacol. 31: 2929–2935, 1982.PubMedCrossRefGoogle Scholar
  35. 35.
    Presant CA, Multhauf P, Klein L et al: Thymidine and 5-FU: A Phase II pilot study in colorectal and breast carcinomas. Cancer Treat. Rep. 67: 735–736, 1983.PubMedGoogle Scholar
  36. 36.
    Vogel SJ, Presant CA, Ratkin GA, Klahr C: Phase I study of thymidine plus 5-fluorouracil infusions in advanced colorectal carcinoma. Cancer Treat. Rep. 63: 1–5, 1979.PubMedGoogle Scholar
  37. 37.
    Sternberg A, Petrelli NJ, Au J et al: A combination of 5-fluorouracil and thymidine in advanced colorectal carcinoma. Cancer Chemother. Pharmacol. 13: 218–222, 1984.PubMedCrossRefGoogle Scholar
  38. 38.
    Ohnuma T, Roboz J, Waxman S et al: Clinical pharmacologic effects of thymidine plus 5-FU. Cancer Treat. Rep. 64: 1169–1177, 1980.PubMedGoogle Scholar
  39. 39.
    Oswald H, Youssef M: Potentiation of the chemotherapeutic action of 5-fluorouracil by combination with cytidine or guanosine on HRS-sarcoma. J. Cancer Res. Clin. Oncol. 93: 241–244, 1979.CrossRefGoogle Scholar
  40. 40.
    Kanzawa F, Hoshi A, Kuretani K: Improvement of therapeutic effect of 5-fluorouracil by orotic acid. J. Pharm. Dyn. 2: 257–259, 1979.Google Scholar
  41. 41.
    Santelli G, Valeriote F: In vivo potentiation of 5-fluorouracil cytotoxicity against AKR leukemia by purines, pyrimidines and their nucleosides and deoxynucleosides. J. Natl. Cancer Inst. 64: 69–72, 1980.PubMedGoogle Scholar
  42. 42.
    Houghton JA, Houghton PJ, Wooten RS: Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine and 5-fluoro-2′-deoxyuridine. Cancer Res. 39: 2406–2413, 1979.PubMedGoogle Scholar
  43. 43.
    Becker AJ, McCulloch EA, Siminovitch L, Till JE: The effect of differing demands for blood cell production on DNA synthesis by hemopoietic colony forming cells of mice. Blood 26: 296–308, 1965.PubMedGoogle Scholar
  44. 44.
    Parker WB, Klubes P: Enhancement by uridine of the anabolism of 5-fluorouracil in mouse T-lymphoma (S-49) cells. Cancer Res. 45: 4249–4256, 1985.PubMedGoogle Scholar
  45. 45.
    Drewinko B, Yang LY, Ho DHW et al: Treatment of cultured human colon carcinoma cells with fluorinated pyrimidines. Cancer 45: 1144–1158, 1980.PubMedCrossRefGoogle Scholar
  46. 46.
    Iigo M, Ando N, Hoshi A, Kuretani K: Effect of pyrimidines, purines and their nucleosides on antitumor activity of 5-fluorouracil against L1210 leukemia. J. Pharm. Dyn. 5: 515–520, 1982.Google Scholar
  47. 47.
    Martin DS, Stolfi RL, Sawyer RC et al: High-dose 5-fluorouracil with delayed uridine “rescue” in mice. Cancer Res. 42: 3964–3970, 1982.PubMedGoogle Scholar
  48. 48.
    Klubes P, Cerna I, Meldon M: Uridine rescue from the lethal toxicity of 5-fluorouracil in mice. Cancer Chemother. Pharmacol. 8: 17–21, 1982.PubMedCrossRefGoogle Scholar
  49. 49.
    Sawyer RC, Stolfi RL, Spiegelman S, Martin DS: Effect of uridine on the metabolism of 5-fluorouracil in the CD8F1, murine mammary carcinoma system. Pharmaceutical Res. 2: 69–75, 1984.CrossRefGoogle Scholar
  50. 50.
    Klubes P, Cerna I: Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil. Cancer Res. 43: 3182–3186, 1983.PubMedGoogle Scholar
  51. 51.
    Leyva A, van Groeningen CJ, Kraal I et al: Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Res. 44: 5928–5933, 1984.PubMedGoogle Scholar
  52. 52.
    Benke PJ, Dittmar D: Phosphoribosylpyrophosphate synthesis in cultured human cells. Science 198: 1171–1173, 1977.PubMedCrossRefGoogle Scholar
  53. 53.
    Yoshida M, Hoshi A, Kuretani K: Prevention of antitumor effect of 5-fluorouracil by hypoxanthine. Biochem. Pharmacol. 27: 2979–2982, 1978.PubMedCrossRefGoogle Scholar
  54. 54.
    Ullman B, Kirsch J: Metabolism of 5-fluorouracil in cultured cells. Protection from 5-fluorouracil cytotoxicity by purines. Mol. Pharmacol. 15: 357–366, 1979.Google Scholar
  55. 55.
    Gotto AM, Belkhode ML, Touster O: Stimulatory effects of inosine and deoxyinosine on the incorporation of uracil 214-C, 5-fluorouracil-2 14-C and 5-bromouracil-214-C into nucleic acids by Ehrlich ascites tumor cells in vitro. Cancer Res. 29: 807–811, 1969.PubMedGoogle Scholar
  56. 56.
    Kessel D, Hall T: Influence of ribose donors on the action of 5-fluorouracil. Cancer Res. 29: 1749–1754, 1969.PubMedGoogle Scholar
  57. 57.
    Cory JG, Crumley J, Wilkinson DS: Evidence for role of purine nucleoside phosphorylase in sensitivity of Novikoff hepatoma cells to 5-fluorouracil. Adv. Enz. Reg. 15: 153–166, 1977.CrossRefGoogle Scholar
  58. 58.
    Evans RM, Laskin JD, Hakala MT: Effects of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res. 41: 3288–3295, 1981.PubMedGoogle Scholar
  59. 59.
    Iigo M, Kuretani K, Hoshi A: Relationship between antitumor effect and metabolites of 5-fluorouracil in combination treatment with 5-fluorouracil and guanosine in ascites sarcoma-180 tumor system. Cancer Res. 43: 5687–5694, 1983.PubMedGoogle Scholar
  60. 60.
    Kessel D, Hall TC, Wodinski I: Nucleotide formation as a determinant of 5-fluorouracil response in mouse leukemias. Science 154: 911–913, 1966.PubMedGoogle Scholar
  61. 61.
    Schwartz PM, Handschumacher RE: Selective antagonism of 5-fluorouracil cytotoxicity by 4-hydroxypyrazolopyrimidine (Allopurinol) in vitro. Cancer Res. 39: 3095–3101, 1979.PubMedGoogle Scholar
  62. 62.
    Schwartz PM, Dunigan JM, Marsh JC, Handschumacher RE: Allopurinol modification of the toxicity and antitumor activity of 5-fluorouracil. Cancer Res. 40: 1885–1889, 1980.PubMedGoogle Scholar
  63. 63.
    Houghton JA, Houghton PJ: Combinations of 5-FU, hypoxanthine and allopurinol in chemotherapy for human colon adenocarcinoma xenografts. Cancer Treat. Rep. 66: 1201–1206, 1982.PubMedGoogle Scholar
  64. 64.
    Howell SB, Wung WE, Taetle R et al: Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer 48: 1281–1289, 1981.PubMedCrossRefGoogle Scholar
  65. 65.
    Campbell TN, Howell SB, Pfeifle C, House BA: High-dose allopurinol modulation of 5-FU toxicity: Phase I trial of an outpatient dose schedule. Cancer Treat. Rep. 66: 1723–1727, 1982.PubMedGoogle Scholar
  66. 66.
    Valeriote F, Van Putten L: Proliferation-dependent cytotoxicity of anticancer agents: A review. Cancer Res. 35: 2619–2630, 1975.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1986

Authors and Affiliations

  • Giovanni Santelli

There are no affiliations available

Personalised recommendations